Search clinical trials for: Amyloidosis, Wild Type

Total 64755 results

iOMEDICO AG
Amgen

Completed

Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE) (VALIDATE)

Metastatic Colorectal Cancer | RAS Wild-type

Germany
Institut Pasteur
Wellcome Trust; Walter Reed Army Institute of Research (WRAIR); Parexel; Bill &... and other collaborators

Completed

A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a (GlycoShig3)

Healthy

Kenya
Hoffmann-La Roche

Completed

A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

Metastatic Melanoma

France, Italy, Spain, Brazil, Latvia, Germany, Hungary, Switzerland
Taizhou Mabtech Pharmaceutical Co.,Ltd

Active, not recruiting

CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Amgen

Completed

Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL

Acute Lymphoblastic Leukemia

Germany, United States, France, Australia, Spain, Italy, Netherlands, Austria, United Kingdom
Memorial Sloan Kettering Cancer Center
Amgen

Active, not recruiting

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

Metastatic Colorectal Cancer

United States
M.D. Anderson Cancer Center

Active, not recruiting

Glutamine PET Imaging Colorectal Cancer

Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | RAS Wild Type

United States
Biotech Pharmaceutical Co., Ltd.
Fudan University; NanJing PLA 81 Hospital

Completed

A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer

Pancreatic Cancer

China
Joaquina Baranda

Active, not recruiting

A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Cancer | Solid Tumor | Malignant Disease | Relapsed Hematologic Malignancy

United States
Novartis Pharmaceuticals

Completed

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Carcinoma, Non-Small-Cell Lung

Italy, Spain, Germany, Japan, Taiwan, Belgium, Netherlands, Singapore, Argentina, France, Israel, Sweden, Korea, Republic of, Lebanon, United Kingdom, United States, Austria, Mexico, Norway, Russian Federation
Daiichi Sankyo
AstraZeneca

Active, not recruiting

Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer (DESTINY-CRC02)

Advanced Colorectal Cancer

Korea, Republic of, United States, Taiwan, Belgium, Spain, Japan, United Kingdom, France, Italy, Australia
French Cardiology Society
Pfizer; Henri Mondor University Hospital

Active, not recruiting

Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement. (AMYLOCARTESIAN)

Aortic Valve Stenosis | Amyloidosis | Aging | Heart Disease

France
GERCOR - Multidisciplinary Oncology Cooperative...
Hoffmann-La Roche

Active, not recruiting

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (STRATEGIC-1)

Colorectal Cancer Metastatic

Ireland, France, Israel
AstraZeneca

Suspended

Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC (SOUND)

Lung Cancer

China
Pfizer

Completed

A Retrospective Validation Study To Identify Chart-Based Clinical Diagnosis Of Wild-Type Transthyretin Amyloid Cardiomyopathy (Attrwt-CM) And Non-Amyloid Heart Failure Among Patients With Heart Failure (HF).

ATTR-CM

United States
Alnylam Pharmaceuticals

Active, not recruiting

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

United States, Poland, Argentina, Australia, Belgium, France, Germany, Japan, Netherlands, Portugal, Spain, Sweden, United Kingdom, Canada, Czechia, Denmark, Hungary, Ireland, Norway, Korea, Republic of, Austria, Croatia, Israel, Latvia, Lithuan... and more
Novartis Pharmaceuticals

Terminated

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Carcinoma, Non-Small-Cell Lung

Belgium, Germany, United States, Canada, France, Italy, Japan, Korea, Republic of, Spain
Fondazione Melanoma Onlus
Clinical Research Technology S.r.l.

Active, not recruiting

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NEO-TIM)

Melanoma

Italy
University of Campania "Luigi Vanvitelli"

Completed

Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial (VELO)

Metastatic Colon Cancer

Italy
Incyte Corporation

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)

Glioblastoma | Adult-type Diffuse Gliomas

United States, Spain, Italy, United Kingdom, Germany, Japan, France, Netherlands, Denmark
Spanish Cooperative Group for the Treatment of...
Amgen

Active, not recruiting

Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (CR-SEQUENCE)

Colorectal Cancer

Spain
Taiho Oncology, Inc.
Institut de Recherches Internationales Servier

Completed

Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients (SUNLIGHT)

Refractory Metastatic Colorectal Cancer

United States, Poland, France, Germany, Hungary, Italy, Russian Federation, Ukraine, Austria, Belgium, Brazil, Denmark, Puerto Rico, Spain
AstraZeneca
Merck Sharp & Dohme LLC

Completed

A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer (FLAME)

Advanced Ovarian Cancer

United States
Novartis Pharmaceuticals

Completed

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-III)

Carcinoma, Non-Small-Cell Lung

Belgium, Germany, Italy, France, Netherlands, Spain, Korea, Republic of, India, Brazil, Portugal
University of Alabama at Birmingham

Terminated

CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients (BRCA)

Ovarian Cancer | Resistant BRCA Wild-Type Ovarian Cancer

United States
Turning Point Therapeutics, Inc.

Active, not recruiting

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1)

Advanced Solid Tumor | Metastatic Solid Tumors | MET Gene Alterations

United States, France, Korea, Democratic People's Republic of, Korea, Republic of, Spain
Ludwig-Maximilians - University of Munich
Merck KGaA, Darmstadt, Germany; ClinAssess GmbH

Active, not recruiting

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

Treatment Related Cancer

Germany
Ferring Pharmaceuticals
Ferring Arzneimittel GmbH

Completed

Effectiveness and Safety of Firmagon® (FAST)

Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma

Germany
Rain Oncology Inc

Withdrawn

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Melanoma | Renal Cell Carcinoma | Gastric Cancer | NSCLC | Mesothelioma | Advanced Solid Tumor | Pancreas Adenocarcinoma | Urothelial Carcinoma Bladder | HNSCC | CDKN2A
University Hospital, Bordeaux

Completed

Neuropathy in Patients Monitored for Wild-type TTR Cardiac Amyloidosis (Non-mutated) (N-SAC)

Wild-type Amyloid Cardiopathy

France
Emory University
Bristol-Myers Squibb; National Cancer Institute (NCI); City of Hope Medical Center and other collaborators

Completed

Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
Universitair Ziekenhuis Brussel

Completed

TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma (TraMel-WT)

Stage IV Melanoma | Stage III Melanoma

Belgium
Centre Leon Berard
Novartis

Completed

Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD)

Colorectal Cancer | Metastatic Cancer | Advanced Cancer

France
Intellia Therapeutics

Active, not recruiting

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)

Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | Wild-Type Transthyretin Cardiac Amyloidosis

France, United Kingdom, New Zealand, Sweden
UNICANCER

Active, not recruiting

Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (PANIRINOX)

Metastatic Colorectal Cancer

France
Assistance Publique - Hôpitaux de Paris

Completed

Cobimetinib for BRAF-wild-type or Mutated Histiocytoses (COBRAH)

Disease or R Group Histiocytoses

France
Federation Francophone de Cancerologie Digestive
Amgen

Active, not recruiting

FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation (OPTIPRIME)

Metastatic Colorectal Cancer

France, Martinique
University of Southern California
National Cancer Institute (NCI); Oncolytics Biotech

Completed

Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
NCIC Clinical Trials Group

Completed

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Colorectal Cancer

Canada
Canadian Cancer Trials Group
Pfizer

Completed

P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.

Metastatic Colorectal Cancer

Canada
Criterium, Inc.
Amgen

Active, not recruiting

FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Colorectal Cancer Metastatic

United States
Bahria University

Completed

To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea

Irritable Bowel Syndrome With Diarrhea

Pakistan
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

Glioblastoma

United States
Philogen S.p.A.

Completed

Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse (GLIOMOON)

Glioma of Brain

Switzerland
Damanhour University
Tanta University

Completed

Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD

Coronary Artery Disease | Diabetes Mellitus, Type 2

Egypt
Washington University School of Medicine

Completed

Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

Astrocytoma, Grade III | Astrocytoma, Grade IV | Grade IV Astrocytoma | Grade III Astrocytoma

United States
Emory University
National Cancer Institute (NCI); GlaxoSmithKline; National Institutes of Health...

Active, not recruiting

Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer (NIPAVect)

Microsatellite Stable | Stage IV Colorectal Cancer AJCC v8 | RAS Wild Type | MSI-H Colorectal Cancer | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors

Glioma | Recurrent Childhood Medulloblastoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Diffuse Intrinsic Pontine Glioma | Refractory Brain Neoplasm | Recurrent Childhood Anaplastic Oligodendroglioma | Recurrent Childhood Glioblastoma | Recurrent Primitive Neuroectodermal Tumor | Childhood Astrocytoma and other conditions

United States
Calithera Biosciences, Inc

Terminated

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Squamous Non-small-cell Lung Cancer | NFE2L2 Gene Mutation | Squamous Non-Small Cell Neoplasm of Lung

United States
Oncology Institute of Southern Switzerland
University of Kiel; Ente Ospedaliero Cantonale, Bellinzona

Completed

Prevalence of Wild Type ATTR

Wild-type Transthyretin Amyloidosis

Switzerland

Search clinical trials for: Amyloidosis, Wild Type

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations